Drugs / DN-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00057031 | Nov 2002 → Mar 2004 | myelodysplastic syndrome | Novacea | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00057031 ↗ |
| Route | Oral | “DN-101 provides MDS patients with high doses of calcitriol in a pill form.” NCT00057031 ↗ |